TapImmune Inc. (NASDAQ:MRKR) saw a significant growth in short interest in the month of October. As of October 31st, there was short interest totalling 5,090,000 shares, a growth of 12.6% from the September 30th total of 4,520,000 shares. Based on an average daily trading volume, of 271,300 shares, the days-to-cover ratio is presently 18.8 days. Currently, 57.4% of the shares of the stock are short sold.
Several research analysts have weighed in on the stock. Piper Jaffray Companies lowered their target price on shares of TapImmune from $10.00 to $6.00 and set an “overweight” rating on the stock in a research report on Wednesday. Nomura reaffirmed a “buy” rating and issued a $16.00 price target on shares of TapImmune in a report on Tuesday, August 13th. ValuEngine raised shares of TapImmune from a “hold” rating to a “buy” rating in a report on Wednesday, October 2nd. Janney Montgomery Scott reduced their price target on shares of TapImmune from $15.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday. Finally, Zacks Investment Research downgraded shares of TapImmune from a “hold” rating to a “sell” rating in a report on Thursday, October 10th. One equities research analyst has rated the stock with a sell rating, six have issued a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $10.15.
Shares of NASDAQ MRKR traded up $0.03 on Friday, hitting $2.86. The company’s stock had a trading volume of 375,700 shares, compared to its average volume of 378,294. TapImmune has a 12-month low of $2.69 and a 12-month high of $9.17. The stock has a 50 day moving average of $4.31 and a 200-day moving average of $5.57. The company has a market capitalization of $129.40 million, a price-to-earnings ratio of -1.71 and a beta of 0.16. The company has a debt-to-equity ratio of 0.01, a current ratio of 15.83 and a quick ratio of 16.85.
TapImmune Company Profile
Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, develops and commercializes novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA T cell technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets.
Recommended Story: Book Value Of Equity Per Share – BVPS Explained
Receive News & Ratings for TapImmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TapImmune and related companies with MarketBeat.com's FREE daily email newsletter.